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Background
Inflammation is a response to external challenge or cellu-
lar injury that leads to the release of several inflammatory
mediators and restoration of tissue structure and function.
On the other hand, inflammation deregulation can cause
tissue damage and is related to many diseases. During
inflammation, a complex program of intracellular signal
transduction and transcription events, driven by multiple
pro-inflammatory mediators and cytokines, is activated.
Ouabain, a potent inhibitor of the Na+, K+-ATPase, was
identified as an endogenous substance of human plasma,
able to affect various immunological processes, such as
lymphocyte proliferation, apoptosis and monocyte func-
tion. These effects are particularly attractive for anti-infla-
matory molecules bioprospection. We have also
demonstrated the ability of ouabain to modulate inflam-
mation, but little is known about the mechanisms
involved.
Aim
The aim of this work was to evaluate, in vivo, the role of
ouabain on NFB e p-38 activity. Additionally, we tested
ouabain effect (1, 10 and 100 nM) on FITC-dextran endo-
cytosis ability of peritoneal cells.
Methods
In all experiments, 0.56mg/kg ouabain or phosphate buf-
fered saline (PBS) was given intraperitoneally (i.p.) for
three consecutive days. After 1h of the last day of ouabain
treatment, mice were euthanized and macrophages and
neutrophils from peritoneal cavity were collected. Cells
were seeded in 24-well plates and incubated for 1h. After
the incubation period, macrophages were tested using
antibodies anti-P-NFB e anti-Pp38 by flow cytometry.
Besides that, ouabain was tested on FITC-dextran endocy-
tosis ability of peritoneal cells. Peritoneal cells from unesti-
mulated animals, including macrophages and neutrophils,
were placed in sterile 96-well plates and incubated with
different concentrations of ouabain (1, 10, 100nM) for 1h.
This was followed by the addition of 0.5 mg/ml of 40 kDa
FITC-dextran. After incubation, cells were washed with
PBS and analyzed by flow cytometry. The FITC-dextran
uptake was determined as the mean fluorescence relative
to the background staining of the respective sample incu-
bated with FITC-dextran at 4°C.
Results
Ouabain treatment decreased basal levels of P-p38 and
P-NFB expression compared to the PBS group. Ouabain
led to a 65% reduction of p38 activation and 60% reduc-
tion of P-NFB. Besides that, ouabain was also capable of
reducing by 84% the expression of both protein NFkB and
p-38 in the double positive cell subpopulation. Finally,
after one hour of incubation, approximately 58% of cells
endocytosed FITC-dextran particles, and this process was
inhibited at 4°C. Moreover, we also observed that ouabain
did not affect the endocytosis of dextran particles.
Conclusion
In agreement with the immunosuppressive effects that
have been previously observed by us, ouabain pretreat-
ment reduced the basal activation of proteins NFB and
p-38, but did not alter in vitro phagocytosis of dextran
particles by peritoneal cells, suggesting a new mode of
action of this substance. The present work reveals ouabain
anti-inflammatory potential with biotechnological appli-
cations related to the immune system. However, further
studies are necessary to elucidate the mechanisms
involved.
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